|
|
cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis
|
|
|
|
|
نویسنده
|
connell nathan t. ,connors jean m.
|
منبع
|
journal of thrombosis and thrombolysis - 2019 - دوره : 48 - شماره : 3 - صفحه:382 -386
|
چکیده
|
Malignancy is a well-established risk factor for venous thromboembolism and while low-molecular-weight heparin therapy has been standard of care for cancer-associated thrombosis for many years, many patients find injection therapy burdensome. the direct oral anticoagulant edoxaban has been shown to be noninferior to dalteparin for the treatment of cancer-associated thrombosis. in a markov simulation model, edoxaban with 6-month time horizon and a united states societal perspective with 2017 us dollars, edoxaban was the preferred strategy in the general cancer population (6-month cost $6061 with 0.34 quality adjusted life years) and in a subgroup of patients with gastrointestinal malignancy (6-month cost $7227 with 0.34 quality adjusted life years). the incremental cost effectiveness ratio of dalteparin compared to edoxaban was $1,873,535 in the general oncology population and $694,058 in the gastrointestinal malignancy population.
|
کلیدواژه
|
cost-effectiveness ,edoxaban ,dalteparin ,cancer-associated thrombosis ,venous thromboembolism
|
آدرس
|
brigham and women’s hospital, hematology division, usa. harvard medical school, usa, brigham and women’s hospital, hematology division, usa. harvard medical school, usa
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|